HepatAssist Bioartificial Liver

An experimental device meant to serve as a bridge for patients with acute liver failure, who were waiting a liver transplant or whose livers needed time to rejuvenate, possibly negating need for transplant
References in periodicals archive ?
The 30-day survival rate for the 147 fulminant hepatic failure patients in the study was 59% for patients randomized to the regular standard of care (SOC) and 73% for patients treated with the standard of care plus the HepatAssist bioartificial liver support system.
the manufacturer of the HepatAssist bioartificial liver support system.